Haberacin

Haberacin Uses, Dosage, Side Effects, Food Interaction and all others data.

An semisynthetic aminoglycoside antibiotic. Often used for treatment of multi-resistant bacterial infection such as methicillin-resistant Staphylococcus aureus (MRSA).

Haberacin is an aminoglycoside. Aminoglycosides function by binding to bacterial 30S ribosomal subunits, causing t-RNA misreads, and preventing the production of proteins. Anaerobes are less susceptible to aminoglycosides because they do not spend as much energy as aerobes on taking up chemicals like aminoglycosides. Aminoglycosides are useful primarily in infections involving aerobic, gram-negative bacteria, such as Pseudomonas, Acinetobacter, and Enterobacter.

Haberacin
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Haberacin
Generic	Arbekacin
Arbekacin Other Names	Arbekacin, Arbekacina, Arbekacine, Arbekacinum, Haberacin
Type
Formula	C₂₂H₄₄N₆O₁₀
Weight	Average: 552.619 Monoisotopic: 552.311891658
Protein binding	3-12%
Groups	Experimental, Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am

Uses

Haberacin is used for the short term treatment of multi-resistant bacterial infections, such as methicillin-resistant Staphylococcus aureus (MRSA).

How Haberacin works

Haberacin irreversibly binds bacterial 30S and 16S ribosomal subunits inhibiting protein synthesis. Haberacin binds to 4 nucleotides of the 16S subunit and 1 amino acid of protein S12 to interfere with the decoding site around nucleotide 1400 in the 16S subunit. Interference with the decoding site interferes with its interaction with the wobble base of tRNA. This hindered interaction causes mRNA to be misread and the incorrect amino acids are inserted into protein. These error filled proteins are not able to function or may even be toxic.

Toxicity

Patients with renal impairment or those taking ototoxic and nephrotoxic drugs are at the highest risk for ototoxicity and nephrotoxicity associated with aminoglycoside use. Normal duration of IM or IV aminoglycoside therapy is 7-10 days. Although a longer duration may be necessary in some cases, toxicity is more likely to occur when aminoglycoside treatment is continued for longer than 10 days.